Yanchik Connealy Pamela
Yanchik Connealy Pamela's purchase track record
Yanchik Connealy Pamela has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/26/2024 | PYXS | $174K | -32.2% | -29.9% | -1.7% |
| 9/22/2023 | PYXS | $56K | +5.3% | +149.4% | +21.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Transaction History
| OBIO | ▲ Buy | Grant | 17,327 | $0 | 6/23/2026 | View on chart |
| OBIO | ▲ Buy | Grant | 15,000 | $0 | 8/7/2025 | View on chart |
| OBIO | ▲ Buy | Grant | 12,422 | $0 | 6/24/2025 | View on chart |
| PYXS | ▲ Buy | Open Market | 5,450 | $11K | 11/26/2024 | View on chart |
| PYXS | ▲ Buy | Open Market | 83,400 | $163K | 11/26/2024 | View on chart |
| OBIO | ▲ Buy | Grant | 5,376 | $0 | 6/20/2024 | View on chart |
| PYXS | ▲ Buy | Grant | 328,710 | $0 | 3/26/2024 | View on chart |
| PYXS | ▼ Sell | Tax Withholding | 36,949 | $52K | 11/29/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 8,000 | $15K | 9/28/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 6,426 | $12K | 9/27/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 12,000 | $20K | 9/25/2023 | View on chart |
| PYXS | ▲ Buy | Open Market | 5,000 | $9K | 9/22/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 187,793 | $0 | 9/7/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 11,667 | $0 | 7/20/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 758 | — | 4/12/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 209,803 | $0 | 3/24/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 3,488 | — | 1/26/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 43,493 | $0 | 1/3/2023 | View on chart |
| PYXS | ▲ Buy | Grant | 93,493 | $0 | 4/14/2022 | View on chart |
| PYXS | ▲ Buy | Grant | 247,524 | $0 | 3/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum
Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.